Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin long-term safety extension in Schizophrenia (CONNEX-X)
NCT05211947Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 40
01
Overview
Phase 3, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment Emergent Adverse Events at 61.9 weeks. Started Mar 2022; status: terminated.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05211947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211947.